Thursday 16 October, 2025
Introduction/Objectives: Infectious diseases are a major cause of childhood morbidity and mortality. Therefore, antibiotics are among the most commonly prescribed drugs…
Read moreAbstracts
Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock
Thursday 16 October, 2025
Objectives: Sepsis is defined as fatal organ dysfunction caused by a dysregulated host response to infection and is associated with…
Read morePopulation pharmacokinetics of aripiprazole and its active metabolite dehydroaripiprazole in subjects receiving once-monthly intramuscular aripiprazole.
Thursday 16 October, 2025
Introduction: Aripiprazole is an antipsychotic whose systemic metabolism is mainly carried out by hepatic biotransformation, mediated by CYP2D6 and, to…
Read moreCorrelation between trough concentrations and AUC of linezolid for sampling optimization in critically ill patients
Thursday 16 October, 2025
Introduction: Linezolid is an oxazolidinone antibiotic used to treat serious infections caused by drug-resistant gram-positive bacteria. Different pharmacokinetic/pharmacodynamic (PK/PD) targets have…
Read moreGeneration of realistic virtual adult populations using the NHANES database: a copula approach
Thursday 16 October, 2025
Introduction: Generation of virtual patient populations which consist of sets of patient-associated covariates is of relevance for pharmacometric simulations of…
Read morepmxcopula – R package for copula-based covariate simulation
Thursday 16 October, 2025
Introduction: Patient characteristics or covariates can inform treatment optimization using pharmacometric simulations. Incorporating realistic sets of patient covariates, i.e. virtual…
Read moreModel-based characterisation of host-directed therapeutics against M. tuberculosis in an in vitro experimental model
Thursday 16 October, 2025
Objectives: Molecules that target the host rather than the pathogen offer an attractive paradigm shift in the treatment of tuberculosis…
Read moreModel-based rationale for the in vitro characterisation of antimicrobial combinations in Buruli Ulcer
Thursday 16 October, 2025
Objectives: Buruli Ulcer (BU) is a chronic skin and soft tissue disease that causes significant disability, particularly among young people in…
Read moreProbability of target attainment and dose optimisation of ceftriaxone in children and neonates
Thursday 16 October, 2025
Objectives: Ceftriaxone is a third-generation cephalosporin exhibiting antimicrobial properties for a broad spectrum of bacteria. In both paediatric and adult…
Read moreSeparating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data
Thursday 16 October, 2025
Introduction: Tamoxifen (TAM) is a prodrug used in the treatment of oestrogen receptor-positive breast cancer, with Z-endoxifen (Z-EDX) being its…
Read more